期刊文献+

原发性高血压患者血清apoB水平与冠心病发病风险的相关性 被引量:1

Relationship between serum apolipoprotein B level and the risk of coronary heart disease in patients with primary hypertension
下载PDF
导出
摘要 目的:探讨原发性高血压患者血清载脂蛋白 B(apoB)水平与冠心病发病风险的相关性。方法入选2011年1月至2015年5月住院接受冠状动脉造影的原发性高血压患者785例,根据冠状动脉造影结果分为单纯性高血压组264例和高血压合并冠心病组521例,所有患者均检测空腹血脂和血糖。比较原发性高血压患者中不同水平血清 apoB 的冠心病发病率;运用多因素逐步 logistic 回归分析血清 apoB 与原发性高血压患者冠心病发病风险的相关性;并通过偏相关分析研究血清 apoB 水平与冠状动脉病变支数的相关性。结果伴有高水平血清 apoB 的原发性高血压患者冠心病的发病率最高(74.9%),明显高于低水平组(P <0.05);进一步通过多因素逐步 logistic 回归分析发现,血清 apoB 为原发性高血压发生冠心病的独立危险因素(OR =8.584,95%CI:4.084~18.043,P <0.001);应用偏相关分析发现,校正相关因素后发现,血清 apoB 水平与冠状动脉病变支数的相关性(r =0.240,P <0.001)。结论血清 apoB 对原发性高血压患者的冠心病发病风险以及冠状动脉病变支数的评估有一定的临床意义。 Objective To explore the relationship between serum apolipoproteinB(apoB)level and the risk of coronary heart disease (CHD)in patients with primary hypertension.Methods In total,785 patients with primary hypertension hospitalized from January 2011 to May 2015 were enrolled and classified into a simple hypertension group (264 cases)and a hypertension combined with CHD group (521 cases)according to the results of coronary angiography.All the patients had fasting lipid profile and fasting blood glucose test.The incidence rate of CHD was analyzed according to the different levels of serum apoB in patients with primary hypertension.Mul-tivariate logistic regression was applied to estimate the relationship between serum apoB and the risk of CHD in patients with primary hy-pertension.Partial correlation analysis was used to analyze the correlation of serum apoB level with the narrowing vessel number of coro-nary artery.Results The incidence rate of coronary heart disease in the group of high serum apoB level was the highest (74.9%),and significantly higher than that of low serum apoB level (P 〈0.05)in patients with primary hypertension.Multivariate logistic regression analysis showed that serum apoB was an independent risk factor for occurrence of CHD in patients with primary hypertension(OR =8.584,95%CI:4.084 ~18.043,P 〈0.001).Partial correlation analysis showed that serum apoB level was positively related with the narrowing vessel number of coronary artery(r =0.240,P 〈0.001)after adjusting relevant factors.Conclusions Serum apoB may have some clinical significance in evaluating the risk of CHD and the narrowing vessel number of coronary artery in the patients with primary hypertension.
出处 《安徽医药》 CAS 2016年第1期62-65,共4页 Anhui Medical and Pharmaceutical Journal
基金 安徽省科技攻关项目(No 09010302083) 安徽省卫生厅医学科研重点项目(No 2010B005)
关键词 冠心病 原发性高血压 coronary heart disease primary hypertension apolipoprotein B
  • 相关文献

参考文献12

  • 1Pranavchand R, Reddy BM. Current status of understanding of the genetic etiology of coronary heart disease [Jl.J Postgrad Med, 2013,59(1) :30 -41.
  • 2Kalil GZ, Haynes WG. Sympathetic nervous system in obesity - re- lated hypertension : mechanisms and clinical implications[ J]. Hy- pertens Res,2012,35( 1 ) :4 - 16.
  • 3Pan L, Lu G, Chen Z. Combined use of apolipoprotein B/apali- poprotein A1 ratio and non - high - density lipoprotein cholesterol before routine clinical lipid measurement in predicting coronary heart disease [ J ]. Coron Artery Dis, 2014,25 ( 5 ) :433 - 438.
  • 4Sniderman AD, Williams K, Contois JH, et al. A meta - analysis of low - densit)~.lipoprotein cholesterol, non - high - density lipopro- tein cholesterol, and apolipoprotein B as markers of cardiovascular risk [ J ]. Circ Cardiovasc Qual Outcomes,2011,4 ( 3 ) : 337 - 345.
  • 5Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. ExecutiveSummary of The Third? Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) [ J]. JA- MA ,2001,285 ( 19 ) :2486 - 2497.
  • 6刘力生.中国高血压防治指南2010[J].中华高血压杂志,2011,19(8):701-708. 被引量:6930
  • 7Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipopro- teins, and their ratios in relation to cardiovascular events with sta- tin treatment[J]. Circulation, 2008, 117(23) : 3002 -3009.
  • 8European Association for Cardiovascular Prevention & Rehabilita- tionl, Reiner Z, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology ( ESC ) and the EUropean Atherosclerosis Society (EAS) [ J]. Eur Heart J, 2011, 32(14): 1769-1818.
  • 9Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk : position statement from the AACC lip- oproteins and vascular diseases division working group on best practices[ J~. Clin Chem, 2009, 55 (3) : 407 - 419.
  • 10Genest J, McPhe~on R, Frohlich J, et al. 2009 Canadian Cardio- vascular Society/Canadian guidelines for the diagnosis and treat- ment of dyslipidemia and prevention of cardiovascular disease in the adult 2009 recommendations [ J ]. Can J Cardiol, 2009, 25 (10) : 567 -579.

二级参考文献37

共引文献6949

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部